Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, psilocybin, mescaline +1 moreLSD, psilocybin, mescaline, 5-MeO-DMT show less
DMT
N,N-dimethyltryptamine
DMT (N,N-dimethyltryptamine) — the spirit molecule, dimitri — is a naturally-occurring psychedelic of the tryptamine class. It is found in dozens of plant species and is produced in mammalian brain tissue. It activates serotonin receptors, disrupting the brain's normal sensory filtering and producing the visual and perceptual intensity characteristic of classical psychedelics.[1]
DMT (N,N-dimethyltryptamine) — the spirit molecule, dimitri — is a naturally-occurring psychedelic of the tryptamine class. It is the structurally simplest psychoactive tryptamine, distinguished by ultra-short action and extreme intensity.[1] DMT is a partial agonist at the serotonin 5-HT₂A receptor,[2] producing its effects by disrupting default sensory filtering and promoting neuroplasticity through intracellular receptor activation.[3]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, psilocybin, mescaline +1 moreLSD, psilocybin, mescaline, 5-MeO-DMT show less
First synthesized in 1931 and first given to humans in 1956 by Hungarian psychiatrist Stephen Szára,[2] DMT remained a scientific curiosity until Rick Strassman's federally authorized IV trials in the early 1990s brought it to public awareness.[3] Multiple Phase 2 trials for depression are now active, and the compound is confirmed as a natural product of mammalian brain tissue.[4]
Subjective effects include geometric visual patterns, complete replacement of ordinary reality, entity encounters, ego dissolution, and profound time alteration. The experience is often described as "more real than real" — a total immersion beginning within seconds, with a resemblance to near-death experiences unique among classical psychedelics.[5] Anxiety, loss of control, and acute disorientation are characteristic unwanted effects.
DMT produces no physical dependence, and no human fatality has been attributed to it alone.[6] The main danger arises with ayahuasca: combining the brew's monoamine oxidase-blocking compounds with antidepressants or other serotonin-raising drugs can cause life-threatening overheating and muscle rigidity.[7][8] Clinical trial data and ayahuasca research provide a solid evidence base, though DMT's role as a naturally produced brain chemical is not yet understood.
History[edit]
Discovery
N,N-Dimethyltryptamine was first synthesized in 1931 by Canadian chemist Richard Manske, with no pharmacological testing at the time.[2] The first human study came in 1956, when Hungarian psychiatrist Stephen Szára injected synthetic DMT into 20 volunteers — reportedly after being refused a supply of LSD by its manufacturer.[2]
Clinical and cultural significance
Rick Strassman conducted the first federally authorized human DMT research in decades between 1990 and 1995, administering IV DMT to approximately 60 volunteers.[9][10] His 2001 book DMT: The Spirit Molecule introduced the compound to popular culture and gave it its best-known nickname.[3]
Prohibition and modern research
DMT was placed in Schedule I in 1970 — before any formal clinical investigation of therapeutic potential.[11] Research resumed after 2018 with neuroimaging studies,[12][13] and multiple Phase 2 trials for depression are now active.[14]
The name "spirit molecule" comes from Strassman's 2001 book and reflects the compound's reputation for producing experiences perceived as encounters with autonomous entities or alternate dimensions. DMT is present in over 50 plant species and has been consumed for centuries as a component of ayahuasca, the traditional Amazonian brew.
Chemistry[edit]
Structural class
DMT belongs to the tryptamine chemical family, sharing its core structure with serotonin, psilocin, and 5-MeO-DMT. Its molecular formula is C₁₂H₁₆N₂. It is the structurally simplest psychoactive tryptamine — carrying no additional ring substituents, unlike Psilocin (which adds a hydroxyl group) or 5-MeO-DMT (which adds a methoxy group).
Natural occurrence
DMT is found naturally in over 50 plant species and is produced in mammalian brain tissue.[4] In ayahuasca, compounds from Banisteriopsis caapi vine block the gut enzyme that normally destroys DMT before it reaches the brain, making it orally active.[15]
Pharmacology[edit]
Mechanism of action
DMT activates serotonin receptors in the brain,[1] disrupting the normal filtering of sensory information and producing the visual and perceptual intensity characteristic of classical psychedelics. A 2023 study found that DMT also triggers structural rewiring of brain connections by activating receptors inside cells — a mechanism distinct from ordinary serotonin signaling and specific to psychedelic compounds.[16]
Pharmacokinetics
How long DMT lasts depends entirely on how it is taken. Smoked or injected, it peaks within seconds and clears within 30 minutes, with a half-life of roughly 9–12 minutes.[17][9] Swallowed alone, it is essentially inactive — the gut destroys nearly 97% before it can reach the brain.[18]
In ayahuasca, Banisteriopsis caapi vine compounds block this gut breakdown, making DMT orally active and extending the experience to 4–5 hours.[15] Certain antidepressants (fluoxetine and paroxetine) block a liver enzyme that clears DMT, raising its blood levels and compounding interaction risks with ayahuasca.[8]
Neuroscience[edit]
Where it acts
DMT produces widespread changes in brain connectivity.[13] The brain's normal resting networks dissolve, and the cortex shifts into a state of high complexity. This effect concentrates in regions responsible for abstract thought and self-perception — which corresponds to the visual intensity and sense of reality replacement during the experience.
Why it matters
DMT promotes rapid structural rewiring in cortical neurons, driven by receptors inside cells rather than on their surface.[16] This may be the biological basis for the window of psychological openness observed after psychedelic sessions in therapeutic research.
DMT is produced in mammalian brain tissue, but its physiological role has not been causally demonstrated.[19] A parallel neuroprotective pathway — through sigma-1 receptors — reduces brain damage in oxygen-deprivation models,[20] though its significance in human DMT use is unknown.
Subjective Effects[edit]
The experience of smoked or injected DMT is unlike anything gradual — ordinary reality is replaced within seconds by geometric complexity, vivid intensity, and profound strangeness. There is no buildup. The environment disappears and something else takes its place, fully formed.
Compared to psilocybin or LSD, DMT at common doses is more likely to produce complete alternate-reality immersion and encounters with entities perceived as autonomous beings. The resemblance to near-death experiences — confirmed under controlled conditions[22] — is unique among classical psychedelics.
First synthesized in 1931 by Richard Manske and first administered to humans in 1956 by Stephen Szára,[4] DMT was largely overlooked by clinical science for decades. Rick Strassman's intravenous studies at the University of New Mexico in the early 1990s revived research interest and brought the compound to public awareness.[5] Multiple Phase 2 trials for depression are now active, and the compound has been confirmed as an endogenous product of mammalian brain tissue.[6]
Subjective effects include geometric visual patterns, entity encounters, ego dissolution, and time alteration. Smoked or intravenous DMT arrives fully formed within seconds — a total replacement of ordinary reality often described as "more real than real," with a phenomenological overlap with near-death experiences unique among classical psychedelics.[7] Anxiety, loss of control, and disorientation from the near-instantaneous onset are characteristic unsought effects.
DMT produces no physical or psychological dependence, and no human fatality has been attributed to the compound alone — trials at doses up to 21.5 mg IV report no serious adverse events.[8] The primary risk is psychological: the near-instantaneous onset eliminates any window for dose adjustment, and the total sensory replacement can produce acute panic; moderate acute tolerance develops during sustained infusion[9] but not with typical single doses. Clinical trial data and decades of longitudinal ayahuasca research provide a solid evidence base, though the compound's endogenous function remains incompletely characterized.
History[edit]
Discovery
N,N-Dimethyltryptamine was first synthesized in 1931 by Canadian chemist Richard Manske during a systematic survey of tryptamine derivatives; no pharmacological testing accompanied the work.[4] In 1946, Oswaldo Gonçalves de Lima isolated an alkaloid from Mimosa tenuiflora root bark in Brazil, though definitive identification as DMT came only in 1959.[4] The first human administration was performed in 1956 by Hungarian psychiatrist Stephen Szára, who injected synthetic DMT intramuscularly into 20 volunteers at 0.7 mg/kg after reportedly being refused a supply of LSD by Sandoz Laboratories.[4]
Clinical and cultural significance
Rick Strassman conducted the first federally authorized human DMT research in decades at the University of New Mexico between 1990 and 1995, administering intravenous DMT to approximately 60 volunteers.[10][11] His dose-response studies established the hallucinogen Rating Scale and remain foundational references for DMT's subjective and physiological effects. His 2001 book DMT: The Spirit Molecule introduced the compound to popular culture and coined its best-known nickname.[5]
Prohibition and modern research
DMT was placed in Schedule I of the United States Controlled Substances Act in 1970 and in Schedule I of the United Nations Convention on Psychotropic Substances in 1971 — before any formal clinical investigation of therapeutic potential.[12] Research resumed in earnest after 2018, led by Timmermann and Carhart-Harris at Imperial College London with landmark neuroimaging studies of intravenous DMT.[13][14] As of 2026, multiple Phase 2 clinical trials for major depressive disorder are active,[15] and novel delivery systems — including buccal[16] and transdermal[17] formulations — are under investigation.
The name "spirit molecule" derives from Strassman's 2001 book and reflects the compound's reputation for producing experiences perceived as encounters with autonomous entities or alternate dimensions of reality. DMT is present in over 50 plant species and has been consumed for centuries as a component of ayahuasca, a traditional Amazonian brew combining DMT-containing plants with Banisteriopsis caapi vine.
Chemistry[edit]
Structural class
DMT belongs to the substituted tryptamine family, sharing its core indole-ethylamine scaffold with psilocin, 5-MeO-DMT, and the neurotransmitter serotonin. The defining structural feature is N,N-dimethylation of the terminal amine — the simplest possible dialkyl substitution — yielding a tertiary amine that is more lipophilic than serotonin while retaining 5-HT₂A binding complementarity.
Unlike ring-substituted relatives such as Psilocin (4-hydroxy-DMT) or 5-MeO-DMT (5-methoxy-DMT), DMT carries no substituents on the indole ring. This makes it the structurally simplest psychoactive tryptamine. The molecule is achiral — it has no stereogenic centers, and no enantiomeric complexity applies to its pharmacology.
Molecular properties
| Molecular formula | C₁₂H₁₆N₂ |
| Molecular weight | 188.27 g/mol |
The molecule consists of a bicyclic indole system (fused pyrrole and benzene rings) connected through C-3 to a two-carbon chain bearing the dimethylamino group. DMT freebase is a white crystalline solid with a melting point of approximately 40–44°C.citation needed The freebase is susceptible to oxidative degradation and should be stored protected from light and air. The fumarate salt (designated SPL026 in clinical trials) is water-soluble and suitable for intravenous administration.[8]
Natural occurrence
DMT occurs endogenously in mammalian brain tissue — Barker et al. detected it in rat pineal gland microdialysate,[6] and subsequent work characterized its distribution across rodent brain regions.[18] The assumed biosynthetic enzyme, indolethylamine N-methyltransferase (INMT), may not be the sole pathway: INMT knockout does not eliminate tryptamine methylation in rats, suggesting alternative enzymatic routes.[19]
In the plant kingdom, DMT is found in over 50 species across diverse families. Mimosa tenuiflora root bark, Psychotria viridis leaves, and various Acacia species contain pharmacologically relevant concentrations. The traditional Amazonian brew ayahuasca combines DMT-containing plant material with Banisteriopsis caapi, whose β-carboline alkaloids (harmine and harmaline) inhibit MAO-A and enable oral bioavailability.[20]
Pharmacology[edit]
Mechanism of action
DMT produces its psychedelic effects primarily through partial agonism at the serotonin 5-HT₂A receptor.[2] Binding affinity at this receptor is lower than that of LSD, but sufficient to produce full hallucinogenic effects at established doses. In rodent models, 5-HT₂A activation drives the characteristic hallucinogenic behavioral response, with metabotropic glutamate receptor 2 contributing a modulatory role.[21]
A key finding published in 2023 revealed that psychedelics including DMT promote cortical neuroplasticity through activation of intracellular 5-HT₂A receptors located on the Golgi apparatus — not the cell-surface receptors that mediate conventional serotonin signaling.[3] Serotonin itself cannot reach these intracellular receptors, suggesting a fundamental distinction between ordinary serotonergic neurotransmission and psychedelic action. DMT has been proposed as the endogenous ligand for these intracellular receptors.[18]
Beyond 5-HT₂A, DMT activates sigma-1 receptors, where it functions as an endogenous agonist with demonstrated neuroprotective effects in oxygen-deprivation models.[22][23] It also agonizes 5-HT₁A receptors (which may temper some hallucinogenic effects) and 5-HT₂C receptors.[21] At monoamine transporters, DMT behaves unusually — as a substrate rather than an inhibitor — at both the SERT and VMAT2, a mechanism that may help the compound accumulate inside cells to reach its intracellular targets.[24] DMT also activates trace amine-associated receptors,[25] though the significance of this remains unclear. No meaningful dopaminergic or adrenergic activity has been detected.[2]
Pharmacokinetics
DMT's pharmacokinetics vary dramatically by route because of extensive first-pass metabolism by MAO-A (MAO-A).
Intravenous
Intravenous DMT fumarate (9–21.5 mg, 10-minute infusion) yields a mean half-life of 9–12 minutes with dose-proportional pharmacokinetics.[1] Effects begin within seconds of bolus injection, peak at 90–120 seconds, and resolve nearly completely within 30 minutes.[10] Extended infusions (up to 120 minutes) confirm that subjective effects plateau within 30 minutes, with moderate acute tolerance developing during sustained delivery.[9]
Smoked and inhaled
Smoked DMT is fully psychoactive without monoamine oxidase inhibition. Metabolism shifts from MAO-dependent to CYP-dependent pathways: the primary urinary metabolite is indole-3-acetic acid (63%), followed by DMT-N-oxide (28%), with unmetabolized DMT accounting for 10%.[26] In a large naturalistic survey (n = 3,778), the median smoked dose was 40 mg with a median experience duration of approximately 10 minutes.[7]
Oral (ayahuasca)
Without MAO-A inhibition, oral DMT is essentially inactive — 97% of the dose is converted to the inactive metabolite indole-3-acetic acid before reaching the brain.[26] Co-administration with harmine (the principal β-carboline in ayahuasca) blocks this metabolism and extends the experience to 4–5 hours. In controlled studies, ayahuasca at DMT doses of 0.6–0.85 mg/kg produced peak effects at 1.5–2 hours.[20] Pharmacokinetic modeling confirms that harmine markedly enhances DMT bioavailability through MAO-A inhibition in liver and lungs.[27][28]
Metabolism
The primary metabolic pathway is MAO-A-mediated oxidative deamination to indole-3-acetic acid.[29][26] A secondary CYP-mediated pathway produces DMT-N-oxide, primarily through CYP2D6.[1] The strong CYP2D6 inhibitors fluoxetine and paroxetine are predicted to increase DMT exposure when co-administered with ayahuasca, compounding the risk of serotonin syndrome.[30]
Neuroscience[edit]
Where it acts
Intravenous DMT produces widespread increases in global functional connectivity across the cortex, with canonical resting-state networks — including the default mode network — losing their modular organization.[14] The effects concentrate in transmodal association cortex, the brain regions responsible for abstract thought and self-referential processing, and correlate with 5-HT₂A receptor density. This pattern — network dissolution, increased neural entropy, and flattened cortical hierarchy — is consistent across DMT, psilocybin, and LSD, though DMT's compressed timeframe makes it uniquely suited for tracking the transition in and out of the psychedelic state.
Electrophysiological recordings show suppression of alpha and beta brain waves during the DMT state, replaced by slower delta and theta activity that tracks with peak visual intensity and immersion.[13] Neural signal complexity rises above waking baseline, approaching levels previously observed only with other classical psychedelics.
Why it matters
DMT is a canonical psychoplastogen — a compound that promotes rapid structural neuroplasticity in cortical neurons.[3] This process occurs through intracellular 5-HT₂A receptors on the Golgi apparatus, driving dendritic growth and increased spine density through downstream signaling cascades. A parallel neuroprotective pathway operates through sigma-1 receptors: DMT attenuated brain damage in oxygen-deprivation models specifically through this mechanism.[23]
The REBUS model (Relaxed Beliefs Under Psychedelics) offers the leading theoretical framework: psychedelics flatten the brain's hierarchical predictive processing by reducing the weight assigned to high-level assumptions, allowing sensory information to dominate. The result may explain both the perceptual intensity of the experience and the therapeutic "window of plasticity" reported after psychedelic sessions.
The physiological role of endogenous DMT — present in mammalian brain tissue and potentially the natural ligand for intracellular 5-HT₂A receptors — has not been causally demonstrated in vivo.[18] The biosynthetic pathway remains uncertain: the assumed enzyme INMT is not essential for tryptamine methylation in rats.[19]
Subjective Effects[edit]
DMT's experiential character depends on its route of administration more than any other classical psychedelic. Smoked and intravenous DMT produce a sudden, complete immersion — ordinary reality is replaced within seconds by a state of extraordinary perceptual richness, geometric complexity, and ontological strangeness. There is no gradual onset; the experience demands immediate psychological surrender. Oral DMT (as ayahuasca) unfolds over hours with a gentler arc, incorporating nausea as an integral phase and permitting greater reflective engagement. Set and setting modulate the experience across all routes, but the compressed timeframe of smoked and intravenous DMT limits any mid-experience adjustment.
Compared to psilocybin and LSD, DMT at common doses produces more frequent entity encounters and immersive alternate-reality experiences, with a quality often described as "more real than real" rather than dreamlike. The phenomenological overlap with near-death experiences is unique among classical psychedelics and has been confirmed under controlled conditions.[31]
Effect Grid
At common doses (smoked: 20–40 mg; IV: 0.2–0.3 mg/kg), the full psychedelic experience emerges. Vivid open- and closed-eye visuals dominate — geometric fractals, color saturation, drifting and morphing of objects, and immersive three-dimensional visual landscapes. Time distortion becomes profound. Thought acceleration and novel conceptual associations arise spontaneously.
Entity encounters become possible at this range. Emotional intensity is high — euphoria may alternate or coexist with anxiety. A sense of the experience being "more real than real" is commonly reported. The altered state completely replaces ordinary sensory experience.
Physically, moderate tachycardia and blood pressure elevation occur. A rushing body sensation accompanies onset. The experience lasts 10–20 minutes (smoked/IV), after which baseline cognition returns rapidly.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual drifting · Symmetrical texture repetition · Spatial disorientation · Environmental patterning · Visual morphing · Tracers · Brightness alteration · Depth perception distortion · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Visual breathing · Visual melting · Vestibular distortion · Synesthesia · Auditory distortion · Music enhancement · Auditory enhancement · Sound sensitivity · Visual diffraction · Visual haze / noise · Visual processing acceleration · Visual magnification · After-images · Auditory misinterpretation · Light sensitivity · Peripheral misidentification · Sensory deprivation · Visual acuity enhancement · Internal hallucinations · Visual recursion · Perspective hallucinations · Object transformations · External hallucinations · Environmental orbism / cubism · Object activation · Auditory hallucinations · Flashbacks · Visual scenery slicing · Visual flipping · Persisting hallucinations
Visual morphing · Tracers · Brightness alteration · Depth perception distortion · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Visual breathing · Visual melting · Vestibular distortion · Synesthesia · Auditory distortion · Music enhancement · Auditory enhancement · Sound sensitivity · Visual diffraction · Visual haze / noise · Visual processing acceleration · Visual magnification · After-images · Auditory misinterpretation · Light sensitivity · Peripheral misidentification · Sensory deprivation · Visual acuity enhancement · Internal hallucinations · Visual recursion · Perspective hallucinations · Object transformations · External hallucinations · Environmental orbism / cubism · Object activation · Auditory hallucinations · Flashbacks · Visual scenery slicing · Visual flipping · Persisting hallucinations
Vibrations / buzzing · Wakefulness · Body schema distortion · Stimulation · Tingling / electric sensations · Bodily pressures · Dizziness · Restlessness · Temperature dysregulation · Tactile euphoria · Bodily heaviness · Bodily lightness · Breathing alteration · Heart rate perception changes · Involuntary body movements · Kundalini-like energy · Laughter fits · Muscle tension · Physical fatigue · Trembling · Appetite suppression · Excessive sweating · Muscle relaxation · Vasoconstriction · Nausea · Diarrhea · Nystagmus (eye wobbles) · Pain suppression · Respiratory stimulation · Vomiting · Sexual arousal enhancement · Nasal congestion · Bodily dissociation · Seizure threshold reduction · Tactile hallucination
Stimulation · Tingling / electric sensations · Bodily pressures · Dizziness · Restlessness · Tactile euphoria · Bodily heaviness · Bodily lightness · Breathing alteration · Heart rate perception changes · Involuntary body movements · Kundalini-like energy · Laughter fits · Muscle tension · Physical fatigue · Trembling · Appetite suppression · Excessive sweating · Muscle relaxation · Vasoconstriction · Nausea · Diarrhea · Nystagmus (eye wobbles) · Pain suppression · Respiratory stimulation · Vomiting · Sexual arousal enhancement · Nasal congestion · Bodily dissociation · Seizure threshold reduction · Tactile hallucination
Thought connectivity · Cognitive flexibility · Pattern recognition enhancement · Cognitive euphoria · Multiple thought streams · Memory suppression · Aesthetic enhancement · Cognitive impairment · Confusion · Immersion enhancement · Introspection enhancement · Openness enhancement · Thought disorganization · Synchronicity · Focus suppression · Increased nature relatedness · Language suppression · Memory fragmentation · Thought loops · Creativity enhancement · Cognitive fatigue · Memory replays · Analysis enhancement · Humor enhancement · Cognitive dysphoria · Information processing enhancement · Amnesia · Delusions · Delirium
Cognitive euphoria · Multiple thought streams · Memory suppression · Aesthetic enhancement · Cognitive impairment · Confusion · Immersion enhancement · Introspection enhancement · Openness enhancement · Thought disorganization · Synchronicity · Focus suppression · Increased nature relatedness · Language suppression · Memory fragmentation · Thought loops · Creativity enhancement · Cognitive fatigue · Memory replays · Analysis enhancement · Humor enhancement · Cognitive dysphoria · Information processing enhancement · Delusions · Delirium
Catharsis · Anxiety · Empathy enhancement · Dysphoria
Sociability suppression · Social disconnection · Disinhibition · Social connection · Ego inflation · Ego dissolution · Boundary dissolution · Cognitive disconnection · Identity alteration · Telepathic feelings
Ego inflation · Ego dissolution · Boundary dissolution · Cognitive disconnection · Identity alteration · Telepathic feelings
Time cessation
Noetic insight · Near-death experience · Death-rebirth sequence · Non-dual awareness · Voidness · Cessation · Transpersonal memory access
Voidness · Cessation · Transpersonal memory access
Recursive awareness
Timeline
First effects emerge 20–45 minutes after ingestion of ayahuasca or oral DMT with MAO inhibitor. Nausea is common during onset and may precede perceptual changes.
Gradual intensification over 30–45 minutes. Visual enhancement, mood shifts, and body sensations build slowly. Nausea and possible vomiting may occur during this phase.
Peak intensity at 1. 5–2 hours post-ingestion. Vivid closed- and open-eye visuals, emotional amplification, introspective depth, and potential entity encounters.
Sustained moderate intensity following peak. Visual and emotional effects persist but gradually diminish. Introspective clarity may increase as the peak intensity subsides.
Gradual return to baseline over 30–60 minutes. Residual visual enhancement and emotional openness persist. Cognitive function normalizes progressively.
Extended reflective state lasting hours. Mood elevation, sense of meaning, and emotional sensitivity may persist. Physical fatigue is common following the extended experience.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Negligible
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 2 hours
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
Acute toxicity
No human fatality has been attributed to DMT alone.[14][7] Clinical trials have administered IV doses up to 21.5 mg and sustained infusions up to 120 minutes, both without serious adverse events.[17][6][23] No liver, kidney, or brain toxicity has been documented at any studied dose.
Heart and circulation
Heart rate and blood pressure rise temporarily during the experience — documented at both IV and oral doses.[10][15][24] All cardiovascular effects resolve as the drug wears off. No studies have examined DMT in people with pre-existing heart conditions.
Psychological risks
Anxiety and loss of control are common, particularly with smoked or IV routes where onset is measured in seconds.[9] The near-instantaneous onset means there is no opportunity to adjust the dose once the experience begins. At higher sustained infusion rates, distressing ego dissolution increases significantly.[23]
A one-year study of 127 regular ayahuasca users found no evidence of psychological deterioration or cognitive decline.[25] No published case reports exist of psychotic episodes or persistent perceptual changes specifically attributed to DMT, though these risks are expected based on its pharmacological class.
Tolerance and dependence
During continuous IV infusion, moderate tolerance develops — effects plateau even as blood levels rise, consistent with receptor desensitization.[26][23] This does not occur with typical single doses, because DMT clears so quickly (half-life 9–12 minutes[17]) that receptors recover between doses.[3]
No physical or psychological dependence has been documented.[25][7] DMT does not meaningfully activate the brain's reward pathways, which explains the absence of compulsive use patterns.
Drug Interactions
Serotonergic medications
The most dangerous interaction involves ayahuasca, which contains compounds that block the enzyme that normally clears DMT. Adding any serotonin-raising medication — SSRIs, SNRIs, tramadol, St. John's wort — creates risk for serotonin syndrome: dangerous overheating, muscle rigidity, uncontrolled jerking, and cardiovascular instability, potentially fatal.[7][8]
With smoked or injected DMT alone — without the ayahuasca vine — SSRI co-administration is less dangerous. Chronic SSRI use typically reduces sensitivity to psychedelics rather than causing a dangerous interaction.
Lithium
Combining DMT with lithium carries a risk of seizures. Lithium lowers the seizure threshold, and activating serotonin receptors may lower it further. Case reports of seizures with LSD and lithium support this concern for psychedelics as a class, though no DMT-specific cases have been published.inferred
Contraindications
6 knownThese contraindications reflect published evidence where available and pharmacological class reasoning where substance-specific data are absent. Absence of DMT-specific data does not imply safety — it indicates an evidence gap.
Absolute contraindications:
- Concurrent MAOI + serotonergic medications: When DMT is taken as ayahuasca, any concurrent serotonergic medication — SSRIs, SNRIs, tramadol, St. John's wort — creates potentially fatal serotonin syndrome risk.[7][8]
- Bipolar I disorder: Activating serotonin receptors may trigger manic episodes. No DMT-specific data on bipolar patients exist.inferred
- Pregnancy and breastfeeding: No reproductive safety data exist.
Relative contraindications:
- Heart conditions: Temporary but significant increases in heart rate and blood pressure are documented.[10][15] Uncontrolled high blood pressure, unstable chest pain, recent heart attack, and severe heart failure are relative contraindications.
- Seizure disorders: Particularly when combined with lithium. The mechanism is pharmacologically plausible but not confirmed with DMT-specific data.inferred
- Personal or family history of psychotic disorders: Standard psychedelic class precaution.inferred
Harm Reduction[edit]
Forms & Identification
DMT appears as freebase crystal or powder for smoking, or as a fumarate salt for clinical IV use. Ayahuasca preparations vary widely in potency — there is no reliable way to gauge concentration without laboratory analysis.
Reagent testing confirms the presence of a tryptamine but cannot distinguish DMT from 5-MeO-DMT, which has a significantly different effective dose range and safety profile. Multiple reagent kits reduce but do not eliminate identification uncertainty.
Guidelines
- Test all material with reagent kits before use. Multiple reagents reduce identification uncertainty.
- Start with a low dose, especially with untested material or a new batch. Potency varies between sources.
- Ensure a sober, trusted sitter is present for any full-dose smoked or IV experience.
- Prepare the physical space: soft surfaces, no sharp objects, low lighting, minimal stimulation.
- For ayahuasca, observe dietary guidelines provided by the facilitator and fast for at least 4 hours beforehand.
- Do not drive or operate machinery for at least 2 hours after smoked/IV DMT, or until the following day after ayahuasca.
- Allow adequate time between experiences — at minimum several days, ideally longer — to process and integrate.
- Use a precise milligram scale for freebase material. Dosing differences of a few milligrams can meaningfully alter the experience.
Set & Setting
Smoked and injected DMT allow no gradual onset — the environment must be fully prepared before administration. A comfortable, quiet, physically safe space with soft surfaces is essential. A sober, trusted sitter should be present for any full-dose experience.
For ayahuasca, the extended duration (4–5 hours) requires sustained comfort, easy bathroom access, and a sitter throughout. Nausea and purging are expected — prepare appropriate containers and hygiene supplies.
Entering the experience in a state of acute anxiety, grief, or interpersonal conflict increases the likelihood of a difficult experience. Intention-setting and emotional centering before administration help establish a constructive frame.
Aftercare & integration. A DMT experience — especially entity encounters or ego dissolution — can leave a lasting impression that benefits from deliberate processing. Write down the experience as soon as possible while details remain fresh. Drawing or visual journaling can capture elements that resist verbal description.
Allow at least one full day of low-demand activity after a significant experience. Avoid making major life decisions in the immediate aftermath. If the experience surfaces difficult emotions or memories, talking with a trusted friend, integration circle, or psychedelic-informed therapist can help. Persistent distress, intrusive imagery, or difficulty distinguishing the experience from reality beyond a few days warrants professional support.
Recovery & Support
DMT does not produce physical dependence, and compulsive use patterns are rare. If use has become a way of avoiding difficult emotions or responsibilities rather than exploring them, that pattern warrants honest self-assessment. Psychedelic integration support is available through the Fireside Project (call or text 62-FIRESIDE) and the Zendo Project — both offer confidential help for people processing difficult experiences or concerned about their use patterns.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most difficult DMT experiences — anxiety, disorientation, overwhelming visuals — are distressing but not medically dangerous and will resolve within minutes (smoked/IV) or hours (ayahuasca). Seek immediate medical help if any of the following occur: seizure activity, loss of consciousness, chest pain, dangerously high body temperature, self-harm behavior, or complete unresponsiveness.
Immediate steps:
- Stay calm and speak in a low, reassuring voice. Remind the person that the effects are temporary.
- If the person is unconscious or vomiting, place them in the recovery position (on their side) to protect the airway.
- Do not physically restrain the person unless they are in immediate danger of harming themselves or others.
- Call emergency services if seizures occur, if the person stops breathing, or if symptoms do not resolve within the expected timeframe.
What to tell the dispatcher: Name the substance (DMT or ayahuasca), approximate amount and time of administration, current symptoms, and any other substances taken. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
DMT is internationally controlled as a Schedule I substance under the 1971 United Nations Convention on Psychotropic Substances.[11] Several jurisdictions grant exemptions for ayahuasca in religious or traditional contexts, treating the botanical preparation differently from isolated DMT.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act, 1970) | Federally controlled since 1971. Religious use exemptions granted to ayahuasca churches (Uniao do Vegetal, Santo Daime). Oregon (2020) and Colorado (2022) removed criminal penalties for personal possession of natural psychedelics[11] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Maximum penalties: possession up to 7 years imprisonment; supply up to life imprisonment |
| Canada | Schedule III (CDSA) | Religious exemptions exist for ayahuasca-using groups |
| European Union | Varies by member state | Controlled at national level in most member states; generally illegal without authorization |
| Australia | Schedule 9 (TGA) | Prohibited substance; no therapeutic or personal use exceptions |
| Brazil | Controlled (isolated DMT); ayahuasca exempt | Ayahuasca legally sanctioned for religious use by federal authorities (2010). Isolated DMT remains controlled |
| United Nations | Schedule I (1971 Convention) | International trade requires strict controls; use restricted to scientific research[11] |
Analog and prodrug considerations
5-MeO-DMT is separately scheduled in some jurisdictions. In the United States, the Federal Analogue Act may apply to unscheduled DMT derivatives if they are substantially similar in structure or effect and intended for human consumption.
Legal status changes frequently and varies within countries as well as between them. Nothing here constitutes legal advice. Verify local law before acting on this information.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Negligible
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 2 hours
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
Acute toxicity
No human fatality has been attributed to DMT alone.[15][29] Phase 1 clinical trials provide the most rigorous safety data: 24 psychedelic-naive healthy subjects received IV DMT fumarate at doses up to 21.5 mg with no serious adverse events.[1][8] Extended infusion protocols (up to 120 minutes at 2.4 mg/min) in 22 participants also produced no serious adverse events.[9] A separate extended-state protocol in 11 volunteers (bolus plus 30-minute infusion) found that anxiety remained low and heart rate habituated within 15 minutes.[32]
No liver, kidney, or brain toxicity has been documented at any studied dose.
Heart and circulation
Temporary increases in heart rate and blood pressure are the primary acute physical risk. Intravenous DMT produces dose-dependent rises in heart rate, blood pressure, body temperature, and pupil diameter.[11] Oral ayahuasca produces moderate blood pressure increases — approximately 9 mmHg diastolic at higher doses — alongside mild heart rate elevation.[20][33]
All cardiovascular effects resolve as the drug wears off. No studies have examined DMT in people with pre-existing heart conditions.
Psychological risks
Anxiety and loss-of-control sensations are common at hallucinogenic doses, particularly with smoked or intravenous routes where onset is measured in seconds.[10] At the lowest hallucinogenic IV dose, Strassman's research found the least desirable effects — physical discomfort and emotional disturbance without the visual and transpersonal phenomena that emerge at higher doses.[10] At higher sustained infusion rates, anxiety and distressing ego dissolution increase significantly.[9]
The near-instantaneous onset of smoked and IV DMT eliminates any possibility of dose titration. Once a full dose is administered, the experience cannot be modulated, and the complete replacement of ordinary sensory reality can be profoundly disorienting.
No published case reports exist of psychotic episodes or HPPD (HPPD) specifically attributed to DMT, though these risks are expected based on its pharmacological class. A one-year study of 127 regular ayahuasca users (twice monthly or more) found no evidence of psychological deterioration, cognitive impairment, or mental health decline compared to controls.[34]
Tolerance and dependence
During continuous IV infusion, moderate acute tolerance develops to subjective effects despite rising plasma concentrations — consistent with receptor desensitization during sustained agonist exposure.[32][9] This tolerance does not appear with sequential single doses, likely because DMT's very short half-life (9–12 minutes[1]) provides insufficient receptor occupancy time to trigger desensitization between doses.[5]
Cross-tolerance with other serotonin 2A receptor agonists (LSD, psilocybin, mescaline, 5-MeO-DMT) is expected based on the shared receptor mechanism but has not been confirmed in a DMT-specific study.inferred
No physical or psychological dependence has been documented in clinical trials, surveys, or longitudinal studies of regular ayahuasca users.[34][29] DMT does not meaningfully activate dopaminergic reward pathways, consistent with the absence of compulsive use patterns.
Drug Interactions
Serotonergic medications
The most dangerous interaction class involves serotonin accumulation. When DMT is taken as ayahuasca (which contains MAO-A inhibitors harmine and harmaline), concurrent use of any serotonergic medication creates risk for serotonin syndrome — a potentially fatal condition involving dangerously high body temperature, muscle rigidity, involuntary jerking, and cardiovascular instability.
SSRIs pose a dual risk with ayahuasca: (1) strong CYP2D6 inhibitors such as fluoxetine and paroxetine increase DMT blood levels; (2) combined serotonin reuptake inhibitor and MAO-A inhibition produce dangerous serotonin accumulation.[30] Tramadol compounds serotonin syndrome risk through similar mechanisms.inferred
With isolated DMT (smoked or IV) — without monoamine oxidase inhibitors — SSRI co-administration is less dangerous. Chronic SSRI use typically reduces 5-HT₂A receptor sensitivity, which may weaken psychedelic effects rather than produce dangerous interactions.
Lithium
The combination of DMT with lithium carries a risk of seizures. Lithium lowers the seizure threshold, and 5-HT₂A activation may further reduce it. Case reports of seizures with LSD and lithium support this concern for psychedelics as a class, though no DMT-specific cases have been published.inferred
Cannabis
No published interaction data exist for DMT combined with cannabis. This is a significant gap given how frequently the two are used together in practice.
Contraindications
6 knownThese contraindications reflect published evidence where available and pharmacological class reasoning where substance-specific data are absent. Absence of DMT-specific data does not imply safety — it indicates an evidence gap.
Absolute contraindications:
- Concurrent MAOI + serotonergic medications: When DMT is taken as ayahuasca, any concurrent serotonergic medication — SSRIs, SNRIs, tramadol, St. John's wort — creates potentially fatal serotonin syndrome risk.[29][30]
- Bipolar I disorder: 5-HT₂A agonism may trigger manic episodes. This is a class-wide contraindication; no DMT-specific data on bipolar patients exist.inferred
- Pregnancy and breastfeeding: No reproductive safety data exist.
Relative contraindications:
- Heart conditions: Temporary but meaningful increases in heart rate and blood pressure are documented at both IV[11] and oral[20] doses. Uncontrolled high blood pressure, unstable chest pain, recent heart attack, and severe heart failure are relative contraindications.
- Seizure disorders: Particularly when combined with lithium. The mechanism is pharmacologically plausible but not confirmed with DMT-specific data.inferred
- Personal or family history of psychotic disorders: Standard psychedelic class precaution based on the potential for 5-HT₂A agonism to trigger psychotic episodes in vulnerable individuals.inferred
Harm Reduction[edit]
Forms & Identification
DMT appears in several distinct forms, each with different dosing precision and risk profiles. Freebase crystal or powder is the most common form for smoking or vaporizing; the fumarate salt is used in clinical settings for intravenous administration. Ayahuasca preparations vary enormously in DMT concentration depending on plant source, preparation method, and batch — there is no reliable way to gauge potency without laboratory analysis.
Reagent testing confirms the presence of a tryptamine but cannot distinguish DMT from closely related compounds such as 5-MeO-DMT, which has a significantly different safety profile and effective dose range. If working with material of unknown identity, testing with multiple reagent kits reduces but does not eliminate identification uncertainty.
Guidelines
- Test all material with reagent kits before use. Multiple reagents reduce identification uncertainty.
- Start with a low dose, especially with untested material or a new batch. Potency varies between sources.
- Ensure a sober, trusted sitter is present for any full-dose smoked or intravenous experience.
- Prepare the physical space: soft surfaces, no sharp objects, low lighting, minimal stimulation.
- For ayahuasca, observe dietary guidelines provided by the facilitator and fast for at least 4 hours beforehand.
- Do not drive or operate machinery for at least 2 hours after smoked/IV DMT, or until the following day after ayahuasca.
- Allow adequate time between experiences — at minimum several days, ideally longer — to process and integrate.
- Use a precise milligram scale for freebase material. Dosing differences of a few milligrams can meaningfully alter the experience.
Set & Setting
The near-instantaneous onset of smoked and intravenous DMT means the environment must be fully prepared before administration — there is no adjustment period. A comfortable, quiet, physically safe space with soft surfaces is essential. Remove sharp objects and obstacles from the immediate area. A sober, trusted sitter should be present for any full-dose experience.
For ayahuasca, the extended duration (4–5 hours) requires sustained environmental comfort, easy bathroom access, and a sitter or facilitator throughout. Nausea and purging are expected and should be prepared for with appropriate containers and hygiene supplies.
Psychological preparation matters across all routes. Entering the experience in a state of anxiety, grief, or interpersonal conflict increases the likelihood of a difficult experience. Intention-setting and emotional centering before administration help establish a constructive frame.
Aftercare & integration. The intensity and strangeness of a DMT experience — particularly entity encounters and ego dissolution — can leave a lasting impression that benefits from deliberate processing. Write down the experience as soon as possible after returning to baseline, while details remain fresh. Drawing or visual journaling can capture elements that resist verbal description.
Allow at least one full day of low-demand activity after a significant experience. Avoid making major life decisions in the immediate aftermath. If the experience surfaces difficult emotions or memories, talking with a trusted friend, integration circle, or psychedelic-informed therapist can help contextualize the material. Persistent distress, intrusive imagery, or difficulty distinguishing the experience from reality beyond a few days warrants professional support.
Recovery & Support
DMT does not produce physical dependence, and compulsive use patterns are rare. If use has become a way of avoiding difficult emotions or responsibilities rather than exploring them, that pattern warrants honest self-assessment. Psychedelic integration therapists and harm reduction organizations such as the Fireside Project (call or text 62-FIRESIDE) and the Zendo Project offer confidential support for people processing challenging psychedelic experiences or concerned about their use patterns.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most difficult DMT experiences — anxiety, disorientation, overwhelming visuals — are distressing but not medically dangerous and will resolve within minutes (smoked/IV) or hours (ayahuasca). Seek immediate medical help if any of the following occur: seizure activity, loss of consciousness, chest pain, dangerously high body temperature, self-harm behavior, or complete unresponsiveness.
Immediate steps:
- Stay calm and speak in a low, reassuring voice. Remind the person that the effects are temporary.
- If the person is unconscious or vomiting, place them in the recovery position (on their side) to protect the airway.
- Do not physically restrain the person unless they are in immediate danger of harming themselves or others.
- Call emergency services if seizures occur, if the person stops breathing, or if symptoms do not resolve within the expected timeframe.
What to tell the dispatcher: Name the substance (DMT or ayahuasca), approximate amount and time of administration, current symptoms, and any other substances taken. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
DMT is internationally controlled as a Schedule I substance under the 1971 United Nations Convention on Psychotropic Substances.[12] Most signatory nations maintain analogous domestic scheduling. A notable exception applies to ayahuasca preparations: several jurisdictions (Brazil, select US religious organizations) have granted exemptions for sacramental use, treating the botanical preparation distinctly from isolated DMT.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act, 1970) | Federally controlled since 1971. Religious use exemptions granted to ayahuasca churches (Uniao do Vegetal, Santo Daime). Oregon (2020) and Colorado (2022) removed criminal penalties for personal possession of natural psychedelics[12] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Maximum penalties: possession up to 7 years imprisonment; supply up to life imprisonment |
| Canada | Schedule III (CDSA) | Religious exemptions exist for ayahuasca-using groups |
| European Union | Varies by member state | Controlled at national level in most member states; generally illegal without authorization |
| Australia | Schedule 9 (TGA) | Prohibited substance; no therapeutic or personal use exceptions |
| Brazil | Controlled (isolated DMT); ayahuasca exempt | Ayahuasca legally sanctioned for religious use by federal authorities (2010). Isolated DMT remains controlled |
| United Nations | Schedule I (1971 Convention) | International trade requires strict controls; use restricted to scientific research[12] |
Analog and prodrug considerations
Several DMT analogs and prodrugs raise scheduling questions. 5-MeO-DMT is separately scheduled in some jurisdictions but not all. psilocybin, the 4-phosphoryloxy prodrug of psilocin (4-hydroxy-DMT), is independently scheduled worldwide. In the United States, the Federal Analogue Act may apply to unscheduled DMT derivatives if they are "substantially similar" in structure or effect and intended for human consumption.
Frequently asked questions
What is DMT?
DMT is an indole alkaloid and substituted tryptamine psychedelic distinguished by its ultra-short duration and endogenous occurrence in mammalian brain. It acts as a 5-HT2A partial agonist and sigma-1 receptor agonist, first synthesized in 1931, with multiple clinical trials now active for depression.
How long does DMT last?
Total duration by route of administration — Smoked: 5 – 15 min; Intravenous: 5 – 20 min; Oral: 3 – 5 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for DMT?
Psychedex publishes a dosage table for DMT on this page covering these routes of administration: smoked, intravenous, oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with DMT?
The highest-severity documented interactions for DMT: MAOIs (Lethal), Alpha-2 adrenergic receptor antagonist (Dangerous), Antihistamines (Dangerous), Clonidine, Guanfacine (Dangerous), Dopamine agonists (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is DMT addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for DMT: tolerance builds rapid; full reset takes 2 hours; cross-tolerance develops with LSD, psilocybin, mescaline, 5-MeO-DMT. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^abRickli A, Moning OD, Hoener MC, Liechti ME (2016) Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens — European Neuropsychopharmacology doi:10.1016/j.euroneuro.2016.05.001
- [2]
- [3]
- [4] ^abcBarker SA, Borjigin J, Lomnicka I, Strassman R (2013) LC/MS/MS analysis of the endogenous dimethyltryptamine hallucinogens, their precursors, and major metabolites in rat pineal gland microdialysate — Biomedical Chromatography doi:10.1002/bmc.2981
- [5] ^abLawrence DW, Carhart-Harris R, Griffiths R, Timmermann C (2022) Phenomenology and content of the inhaled N,N-dimethyltryptamine (N,N-DMT) experience — Scientific Reports doi:10.1038/s41598-022-11999-8
- [6] ^abJames E, Erritzoe D, Benway T, Joel Z, Timmermann C (2024) Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial — Frontiers in Psychiatry doi:10.3389/fpsyt.2023.1305796
references
- [1]
- [2] ^abcRickli A, Moning OD, Hoener MC, Liechti ME (2016) Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens — European Neuropsychopharmacology doi:10.1016/j.euroneuro.2016.05.001
- [3] ^abcVargas MV, Dunlap LE, Dong C, Carter SJ, Tombari RJ, et al. (2023) Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors — Science doi:10.1126/science.adf0435
- [4]
- [5]
- [6] ^abcBarker SA, Borjigin J, Lomnicka I, Strassman R (2013) LC/MS/MS analysis of the endogenous dimethyltryptamine hallucinogens, their precursors, and major metabolites in rat pineal gland microdialysate — Biomedical Chromatography doi:10.1002/bmc.2981